Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer

Cancer Research

Volumn 64, Issue 16, 2004, Pages 5882-5890

  Zhang, Zhen ^a   Bast Jr , Robert C ^b   Yu, Yinhua ^b   Li, Jinong ^a   Sokoll, Lori J ^a   Rai, Alex J ^a   Rosenzweig, Jason M ^a   Cameron, Bonnie ^a   Wang, Young Y ^a   Meng, Xiao Ying ^c   Berchuck, Andrew ^d   Van Haaften Day, Carolien ^e   Hacker, Neville F ^e   De Bruijn, Henk W A ^f   Van Der Zee, Ate G J ^f   Jacobs, Ian J ^g   Fung, Eric T ^c   Chan, Daniel W ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c CIPHERGEN BIOSYSTEMS INC   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e ROYAL HOSPITAL FOR WOMEN   (Australia)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; BIOLOGICAL MARKER; CA 125 ANTIGEN; INTER ALPHA TRYPSIN INHIBITOR; INTER ALPHA TRYPSIN INHIBITOR HEAVY CHAIN H4; PREALBUMIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER SURVIVAL; COLON CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; DOWN REGULATION; EARLY DIAGNOSIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEOMICS; UPREGULATION; VALIDATION PROCESS;

AMINO ACID SEQUENCE; APOLIPOPROTEIN A-I; CA-125 ANTIGEN; FEMALE; HUMANS; IMMUNOASSAY; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM STAGING; OVARIAN NEOPLASMS; PREALBUMIN; PREDICTIVE VALUE OF TESTS; PROTEIN ARRAY ANALYSIS; PROTEOMICS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 4143067096     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0746     Document Type: Article

References (50)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA - Cancer J Clin 2002;52:23-47.
2. Bast RC Jr, Xu FJ, Yu YH, et al. CA 125: the past and the future. Int J Biol Markers 1998;13:179-87.
3. Jacobs IJ, Skates SJ, MacDonald N, et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999;353:1207-10.
4. van Nagell JR Jr, DePriest PD, Reedy MB, et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 2000;77:350-6.
5. Hayashi H, Yaginuma Y, Kitamura S, et al. Bilateral oophorectomy in asymptomatic women over 50 years old selected by ovarian cancer screening. Gynecol Obstet Investig 1999;47:58-64.
6. Menon U, Jacobs I. Screening for ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2002;16:469-82.
7. van Haaften-Day C, Shen Y, Xu F, et al. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer (Phila) 2001;92:2837-44.
8. Zhang Z, Barnhill SD, Zhang H, et al. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecol Oncol 1999;73:56-61.
9. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7.
10. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
11. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-47.
12. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;48:1296-304.
13. Qu Y, Adam BL, Yasui Y, et al. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 2002;48:1835-43.
14. Hutchens TW, Yip TT. New desorption strategies for the mass spectrometric analysis of micromolecules. Rapid Commun Mass Spectrom 1993;7:576-80.
15. Fung ET, Thulasiraman V, Weinberger SR, Dalmasso EA. Protein biochips for differential profiling. Curr Opin Biotechnol 2001;12:65-9.
16. Vapnik VN. Statistical learning theory. Wiley-Interscience; 1998. p. 736.
17. Rai AJ, Zhang Z, Rosenzweig J, et al. Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med 2002;126:1518-26.
18. Zhang Z, Page G, Zhang H. Applying classification separability analysis to microarray data. In: Lin SM, Johnson KF, editors. Methods of microarray data analysis: papers from CAMDA '00. Boston: Kluwer Academic Publishers; 2001. p. 125-36.
19. Zhang Z, Page G, Zhang H. Fishing expedition-a supervised approach to extract patterns from a compendium of expression profiles. In: Lin SM, Johnson KF, editors. Microarray data analysis II: papers from CAMDA '01. Boston: Kluwer Academic Publishers; 2002.
20. Metz CE. Basic principles of ROC analysis. Semin Nucl Med 1978;8:283-98.
21. Jungner I, Marcovina SM, Walldius G, et al. Apolipoprotein B and A-I values in 147576 Swedish males and females, standardized according to the World Health Organization-International Federation of Clinical Chemistry First International Reference Materials. Clin Chem 1998;44:1641-9.
22. Bachorik PS, Lovejoy KL, Carroll MD, Johnson CL. Apolipoprotein B and AI distributions in the United States, 1988-1991: results of the National Health and Nutrition Examination Survey III (NHANES III). Clin Chem 1997;43:2364-78.
23. Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989;4:1-12,
24. Coussens LM, Werb Z. Inflammation and cancer. Nature (Lond) 2002;420:860-7.
25. Diamandis EP. Proteomic patterns in serum and identification of ovarian cancer. Lancet 2002;360:170.
26. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst (Bethesda) 2004;96:353-6.
27. Mahlck CG, Grankvist K. Plasma prealbumin in women with epithelial ovarian carcinoma. Gynecol Obstet Investig 1994;37:135-40.
28. Kuesel AC, Kroft T, Prefontaine M, Smith IC. Lipoprotein(a) and CA125 levels in the plasma of patients with benign and malignant ovarian disease. Int J Cancer 1992;52:341-6.
29. van Bennekum AM, Wei S, Gamble MV, et al. Biochemical basis for depressed serum retinol levels in transthyretin-deficient mice. J Biol Chem 2001;276:1107-13.
30. Roberts D, Williams SJ, Cvetkovic D, et al. Decreased expression of retinol-binding proteins is associated with malignant transformation of the ovarian surface epithelium. DNA Cell Biol 2002;21:11-9.
31. Giordano TJ, Shedden KA, Schwartz DR, et al. Organ-specific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles. Am J Pathol 2001;159:1231-8.
32. Cvetkovic D, Williams SJ, Hamilton TC. Loss of cellular retinol-binding protein 1 gene expression in microdissected human ovarian cancer. Clin Cancer Res 2003;9:1013-20.
33. Pu XP, Iwamoto A, Nishimura H, Nagasawa S. Purification and characterization of a novel substrate for plasma kallikrein (PK-120) in human plasma. Biochim Biophys Acta 1994;1208:338-43.
34. Nishimura H, Kakizaki I, Muta T, et al. cDNA and deduced amino acid sequence of human PK-120, a plasma kallikrein-sensitive glycoprotein. FEBS Lett 1995;357:207-11.
35. Diamandis EP, Yousef GM. Human tissue kallikreins: a family of new cancer biomarkers. Clin Chem 2002;48:1198-205.
36. Yousef GM, Polymeris ME, Yacoub GM, et al. Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res 2003;63:2223-7.
37. Yousef GM, Diamandis EP. Kallikreins, steroid hormones and ovarian cancer: is there a link? Minerva Endocrinol 2002;27:157-66.
38. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 2004;3:367-78.
39. Mok SC, Chao J, Skates S, et al. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst (Bethesda) 2001:93:1458-64.
40. Matrisian LM, Sledge GW Jr, Mohla S. Extracellular proteolysis and cancer: meeting summary and future directions. Cancer Res 2003;63:6105-9.
41. Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev 2001;22:184-204.
42. Petricoin EF III, Ornstein DK, Paweletz CP, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002;94:1576-8.
43. Banez LL, Prasanna P, Sun L, et al. Diagnostic potential of serum proteomic patterns in prostate cancer. J Urol 2003;170:442-6.
44. Adam BL, Qu Y, Davis JW, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002;62:3609-14.
45. Lawrie LC, Curran S, McLeod HL, Fothergill JE, Murray GI. Application of laser capture microdissection and proteomics in colon cancer. Mol Pathol 2001;54:253-8.
46. Vlahou A, Schellhammer PF, Mendrinos S, et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 2001:158:1491-502.
47. Kozak KR, Amneus MW, Pusey SM, et al. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: Potential use in diagnosis and prognosis. Proc Natl Acad Sci USA 2003;100:12343-8.
48. Baggerly KA, Morris JS, Coombes KR. Reproducibility of SELD1-TOF protein patterns in serum: comparing data sets from different experiments. Bioinformatics 2004;20:777-85.
49. Woolas RP, Conaway MR, Xu F. et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol 1995;59:111-6.
50. Skates SJ, Pauler DK, Jacobs I. Screening based on the risk of cancer calculation from Bayesian hierarchical changepoint and mixture models of longitudinal markers. J Am Stat Assoc 2001:96:429-39.